Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett 2024;584:216608.
PMID: 38199587